July 24, 2018
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, announced positive top-line results for its phase III study of EM-100 ophthalmic solution.
September 14, 2017
"We are excited to have Paul join Eton’s board and Chair our Audit Committee. His extensive financial leadership experience within the pharmaceutical industry will be a valuable asset to Eton."
September 7, 2017
"We are pleased to welcome Dr. Riedel to Eton's board and look forward to his scientific expertise in supporting Eton's pipeline."
June 23, 2017
Mr. Brynjelsen will develop and execute a strategy to drive near and long-term growth through the development of Eton’s branded product candidate pipeline and by acquiring and in-licensing new products.
July 24, 2018
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, announced positive top-line results for its phase III study of EM-100 ophthalmic solution.
September 14, 2017
"We are excited to have Paul join Eton’s board and Chair our Audit Committee. His extensive financial leadership experience within the pharmaceutical industry will be a valuable asset to Eton."
September 7, 2017
"We are pleased to welcome Dr. Riedel to Eton's board and look forward to his scientific expertise in supporting Eton's pipeline."
June 23, 2017
Mr. Brynjelsen will develop and execute a strategy to drive near and long-term growth through the development of Eton’s branded product candidate pipeline and by acquiring and in-licensing new products.